-+ 0.00%
-+ 0.00%
-+ 0.00%

MIRA Pharmaceuticals Reports Data From Its SKNY-1 Oral Formulation To Treat Obesity, Addiction-Related Disorders

Benzinga·07/06/2026 13:08:58
Listen to the news

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating the optimized oral formulation of SKNY-1, the Company's oral drug candidate being developed for obesity and addiction-related disorders.